Why Minerva Neurosciences Stock Is Cratering Today
Shares of Minerva Neurosciences (NASDAQ: NERV) dropped by as much as 27.4% in pre-market trading Thursday morning.
What's sending shareholders to the exits? The biotech's stock is cratering this morning in response to a disappointing phase 2b trial readout for the experimental depression medication MIN-117. Minerva was evaluating the drug as a treatment for adults with moderate to severe major depressive disorder (MDD), but it reportedly missed both its primary endpoint and key secondary endpoints.
Image source: Getty Images.
Source Fool.com
